Nervomatrix

Company Overview

Snapshot

Founded in July 2007, Nervomatrix operates with 1–10 employees. The company has raised $3.5 million across one funding round from Everett Partners. In August 2015, Nervomatrix reported successful trial results for its back pain system from a study conducted at Belgium's Free University of Brussels.

Business overview

Nervomatrix is a Health Tech & Life Sciences company specializing in noninvasive, targeted neurostimulation for pain relief. Its core product, Soleve Auto-Targeted Neurostimulation, is a system designed to alleviate chronic lower-back pain without requiring injections, steroids, or drugs. The technology utilizes an array of miniature probes, an automated robotic system, and an electrical measurement and stimulation system to map skin impedance and identify potential active trigger points for targeted electrical stimulation. Nervomatrix operates within the medical devices, digital healthcare, and medical treatment & therapeutics sectors, serving healthcare providers and clinics.

Strategic signal

In August 2015, Nervomatrix announced successful trial results for its low back pain system from a study at Belgium's Free University of Brussels. This validation of its targeted hyper-stimulation therapy demonstrates the efficacy of its technology and signals potential for broader adoption and market expansion in the medical device industry.

Company Intelligence Q&A

What is Nervomatrix's core product?

Nervomatrix has developed Soleve Auto-Targeted Neurostimulation, a system that provides soothing relief for chronic lower-back pain through noninvasive methods, avoiding injections, steroids, or drugs.

When did Nervomatrix receive its Series A investment and from whom?

In October 2011, Nervomatrix received a $3.5 million Series A investment from Everett Partners. This funding was intended to establish its North American sales and marketing headquarters in Akron, Ohio, fund product enhancements, and conduct post-clinical studies.

What was a significant clinical milestone for Nervomatrix?

In August 2015, Nervomatrix reported successful trial results from a study conducted at Belgium's Free University of Brussels for its low back pain system. The study evaluated targeted hyper-stimulation therapy and showed a significant difference between intervention and controlled groups.

When did Nervomatrix receive FDA approval for its device?

In March 2011, Nervomatrix received US FDA approval to market its medical device for the relief of lower back pain. The device uses electrical signals to scan the back and pinpoint pain locations, then applies a gentle electrical current to stimulate nerves and reduce pain.

What are Nervomatrix's plans for market expansion following FDA approval?

Following FDA approval in March 2011, Nervomatrix planned to conduct additional clinical studies at New York University and aimed to have its device in 10 to 20 pain clinics in the US over the subsequent year, licensing the device on a pay-per-use model.